Chinese General Practice ›› 2023, Vol. 26 ›› Issue (03): 356-366.DOI: 10.12114/j.issn.1007-9572.2022.0544
• Evidence-based Medicine • Previous Articles Next Articles
Received:
2022-04-06
Revised:
2022-08-12
Published:
2023-01-20
Online:
2022-09-30
Contact:
LIU Annuo
About author:
通讯作者:
刘安诺
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0544
第一作者 | 发表时间(年) | 国家/地区 | 中心数量 | 研究类型 | 样本量(例) | 诊断标准 | 影响因素 | NOS评分(分) | |
---|---|---|---|---|---|---|---|---|---|
病例组 | 对照组 | ||||||||
ABELE-HORN[ | 1998 | 德国 | 3 | 队列研究 | 48 | 49 | a | ①⑬⑭⑮⑰(21) | 9 |
MARSHALL[ | 1999 | 美国 | 13 | 队列研究 | 224 | 641 | b | ⑧⑭⑮ | 9 |
PI-YING[ | 2005 | 中国 | 8 | 队列研究 | 538 | 1 225 | b | ⑦⑧⑱(21) | 8 |
TAPIA[ | 2006 | 南美 | 16 | 队列研究 | 446 | 1 379 | b | ⑭⑮⑱⑲(21) | 8 |
HENDERSON-SMART[ | 2006 | 澳大利亚+新西兰 | 25 | 队列研究 | 2 710 | 8 743 | b | ⑨ | 8 |
GUIMARÃES[ | 2010 | 葡萄牙 | 5 | 队列研究 | 33 | 223 | c | ⑧⑰⑳(21) | 7 |
FARSTAD[ | 2011 | 挪威 | 全国 | 队列研究 | 324 | 53 | c | ⑬⑭⑱ | 8 |
GORTNER[ | 2011 | 欧洲 | 10国 | 队列研究 | 677 | 3 508 | b | ③⑨⑩⑪ | 8 |
GAGLIARDI[ | 2011 | 意大利 | 14 | 队列研究 | 196 | 1 064 | c | ⑨⑩⑯(21) | 9 |
ROJAS[ | 2012 | 哥伦比亚 | 8 | 病例对照研究 | 64 | 148 | c | ②⑮⑱(21) | 7 |
YEN[ | 2013 | 中国 | 21 | 队列研究 | 2 006 | 3 747 | b | ④⑦⑧⑨⑰⑱(21) | 9 |
KLINGER[ | 2013 | 以色列 | 28 | 队列研究 | 1 663 | 10 476 | b | ③⑨⑩⑫ | 8 |
TOLIA[ | 2014 | 美国 | 200 | 队列研究 | 3 011 | 3 199 | b | ⑦⑩⑮ | 9 |
LAPCHAROENSAP[ | 2015 | 美国 | 116 | 队列研究 | 7 081 | 7 971 | b | ②③⑤⑨⑪ | 7 |
ROCHA[ | 2019 | 葡萄牙 | 11 | 队列研究 | 119 | 375 | c | ④⑤⑮ | 8 |
VALENZUELA-STUTMAN[ | 2019 | 智利 | 15 | 队列研究 | 2 580 | 13 827 | d | ⑥⑨⑫⑭⑯⑰⑱⑲(21) | 7 |
JUNG[ | 2019 | 韩国 | 69 | 队列研究 | 1 906 | 2 756 | c | ⑨⑰ | 9 |
EUISEOK[ | 2019 | 韩国 | 64 | 队列研究 | 816 | 618 | c | ⑨⑬⑱⑳(21) | 9 |
江苏省新生儿重症监护病房母乳质量改进临床研究协作组[ | 2019 | 中国 | 19 | 病例对照研究 | 191 | 577 | c | ⑮⑰(21) | 8 |
SHIN[ | 2020 | 韩国 | KNN | 队列研究 | 764 | 1 603 | c | ①⑦⑨⑩⑰⑱ | 9 |
NAKASHIMA[ | 2021 | 日本 | 218 | 队列研究 | 7 792 | 9 334 | c | ①⑩⑱ | 8 |
FALEH[ | 2021 | 瑞士 | 9 | 队列研究 | 138 | 1 087 | c | ⑭⑱ | 8 |
LI[ | 2021 | 中国 | 33 | 队列研究 | 181 | 446 | b | ⑥⑨⑫⑯ | 7 |
Table 1 Baseline characteristics of the included literature and the quality evaluation outcomes
第一作者 | 发表时间(年) | 国家/地区 | 中心数量 | 研究类型 | 样本量(例) | 诊断标准 | 影响因素 | NOS评分(分) | |
---|---|---|---|---|---|---|---|---|---|
病例组 | 对照组 | ||||||||
ABELE-HORN[ | 1998 | 德国 | 3 | 队列研究 | 48 | 49 | a | ①⑬⑭⑮⑰(21) | 9 |
MARSHALL[ | 1999 | 美国 | 13 | 队列研究 | 224 | 641 | b | ⑧⑭⑮ | 9 |
PI-YING[ | 2005 | 中国 | 8 | 队列研究 | 538 | 1 225 | b | ⑦⑧⑱(21) | 8 |
TAPIA[ | 2006 | 南美 | 16 | 队列研究 | 446 | 1 379 | b | ⑭⑮⑱⑲(21) | 8 |
HENDERSON-SMART[ | 2006 | 澳大利亚+新西兰 | 25 | 队列研究 | 2 710 | 8 743 | b | ⑨ | 8 |
GUIMARÃES[ | 2010 | 葡萄牙 | 5 | 队列研究 | 33 | 223 | c | ⑧⑰⑳(21) | 7 |
FARSTAD[ | 2011 | 挪威 | 全国 | 队列研究 | 324 | 53 | c | ⑬⑭⑱ | 8 |
GORTNER[ | 2011 | 欧洲 | 10国 | 队列研究 | 677 | 3 508 | b | ③⑨⑩⑪ | 8 |
GAGLIARDI[ | 2011 | 意大利 | 14 | 队列研究 | 196 | 1 064 | c | ⑨⑩⑯(21) | 9 |
ROJAS[ | 2012 | 哥伦比亚 | 8 | 病例对照研究 | 64 | 148 | c | ②⑮⑱(21) | 7 |
YEN[ | 2013 | 中国 | 21 | 队列研究 | 2 006 | 3 747 | b | ④⑦⑧⑨⑰⑱(21) | 9 |
KLINGER[ | 2013 | 以色列 | 28 | 队列研究 | 1 663 | 10 476 | b | ③⑨⑩⑫ | 8 |
TOLIA[ | 2014 | 美国 | 200 | 队列研究 | 3 011 | 3 199 | b | ⑦⑩⑮ | 9 |
LAPCHAROENSAP[ | 2015 | 美国 | 116 | 队列研究 | 7 081 | 7 971 | b | ②③⑤⑨⑪ | 7 |
ROCHA[ | 2019 | 葡萄牙 | 11 | 队列研究 | 119 | 375 | c | ④⑤⑮ | 8 |
VALENZUELA-STUTMAN[ | 2019 | 智利 | 15 | 队列研究 | 2 580 | 13 827 | d | ⑥⑨⑫⑭⑯⑰⑱⑲(21) | 7 |
JUNG[ | 2019 | 韩国 | 69 | 队列研究 | 1 906 | 2 756 | c | ⑨⑰ | 9 |
EUISEOK[ | 2019 | 韩国 | 64 | 队列研究 | 816 | 618 | c | ⑨⑬⑱⑳(21) | 9 |
江苏省新生儿重症监护病房母乳质量改进临床研究协作组[ | 2019 | 中国 | 19 | 病例对照研究 | 191 | 577 | c | ⑮⑰(21) | 8 |
SHIN[ | 2020 | 韩国 | KNN | 队列研究 | 764 | 1 603 | c | ①⑦⑨⑩⑰⑱ | 9 |
NAKASHIMA[ | 2021 | 日本 | 218 | 队列研究 | 7 792 | 9 334 | c | ①⑩⑱ | 8 |
FALEH[ | 2021 | 瑞士 | 9 | 队列研究 | 138 | 1 087 | c | ⑭⑱ | 8 |
LI[ | 2021 | 中国 | 33 | 队列研究 | 181 | 446 | b | ⑥⑨⑫⑯ | 7 |
影响因素 | 敏感性分析前 | 敏感性分析后 | ||||
---|---|---|---|---|---|---|
OR值 | 95%CI | P值 | OR值 | 95%CI | P值 | |
母亲合并绒毛膜羊膜炎 | 1.46 | (1.18,1.80) | 0.000 6 | 1.34 | (1.11,1.62) | 0.000 2 |
母亲合并妊娠期高血压 | 1.26 | (1.15,1.37) | <0.000 01 | 1.23 | (1.14,1.33) | <0.000 01 |
母亲合并胎膜早破 | 1.18 | (1.10,1.26) | <0.000 01 | 1.18 | (1.10,1.26) | <0.000 01 |
母亲产前使用类固醇 | 2.38 | (0.15,37.76) | 0.54 | 2.38 | (0.15,37.76) | 0.53 |
母亲合并子痫前期 | 1.74 | (0.31,9.82) | 0.53 | 1.74 | (0.31,9.82) | 0.53 |
母亲合并妊娠期糖尿病 | 1.50 | (0.35,6.44) | 0.58 | 0.80 | (0.23,2.75) | 0.72 |
早产儿出生体质量 | 0.79 | (0.76,0.83) | <0.000 01 | 0.79 | (0.76,0.83) | <0.000 01 |
早产儿胎龄 | 0.80 | (0.73,0.87) | <0.000 01 | 0.77 | (0.71,0.85) | <0.000 01 |
早产儿SGA | 2.64 | (1.85,3.77) | <0.000 01 | 2.46 | (1.74,3.47) | <0.000 01 |
早产儿产房气管插管 | 2.50 | (1.39,4.50) | 0.002 | 2.50 | (1.39,4.51) | 0.002 |
早产儿5 min Apgar评分<7分 | 2.47 | (1.36,4.47) | 0.003 | 2.47 | (1.36,4.47) | 0.003 |
男性早产儿 | 1.49 | (1.43,1.55) | <0.000 01 | 1.49 | (1.43,1.55) | <0.000 01 |
早产儿机械通气 | 1.59 | (1.28,1.96) | <0.000 1 | 1.39 | (1.14,1.71) | <0.000 1 |
早产儿机械通气>7 d | 7.99 | (4.47,14.29) | <0.000 01 | 6.55 | (3.63,11.80) | <0.000 01 |
早产儿肺表面活性物质 | 3.46 | (1.96,6.11) | <0.000 1 | 3.46 | (1.96,6.11) | <0.000 1 |
早产儿使用类固醇 | 2.42 | (1.93,3.03) | <0.000 01 | 2.51 | (1.86,3.40) | <0.000 1 |
早产儿RDS | 3.40 | (2.01,5.75) | <0.000 01 | 3.23 | (1.93,5.41) | <0.000 01 |
早产儿PDA | 1.96 | (1.38,2.79) | 0.000 2 | 1.96 | (1.38,2.80) | 0.000 2 |
早产儿败血症 | 1.82 | (1.36,2.44) | <0.000 1 | 1.74 | (1.30,2.34) | <0.000 1 |
早产儿NEC | 1.62 | (1.18,2.22) | 0.003 | 1.62 | (1.18,2.22) | 0.003 |
早产儿ROP | 1.83 | (0.80,4.14) | 0.15 | 1.83 | (0.80,4.14) | 0.15 |
Table 2 Sensitivity analysis results
影响因素 | 敏感性分析前 | 敏感性分析后 | ||||
---|---|---|---|---|---|---|
OR值 | 95%CI | P值 | OR值 | 95%CI | P值 | |
母亲合并绒毛膜羊膜炎 | 1.46 | (1.18,1.80) | 0.000 6 | 1.34 | (1.11,1.62) | 0.000 2 |
母亲合并妊娠期高血压 | 1.26 | (1.15,1.37) | <0.000 01 | 1.23 | (1.14,1.33) | <0.000 01 |
母亲合并胎膜早破 | 1.18 | (1.10,1.26) | <0.000 01 | 1.18 | (1.10,1.26) | <0.000 01 |
母亲产前使用类固醇 | 2.38 | (0.15,37.76) | 0.54 | 2.38 | (0.15,37.76) | 0.53 |
母亲合并子痫前期 | 1.74 | (0.31,9.82) | 0.53 | 1.74 | (0.31,9.82) | 0.53 |
母亲合并妊娠期糖尿病 | 1.50 | (0.35,6.44) | 0.58 | 0.80 | (0.23,2.75) | 0.72 |
早产儿出生体质量 | 0.79 | (0.76,0.83) | <0.000 01 | 0.79 | (0.76,0.83) | <0.000 01 |
早产儿胎龄 | 0.80 | (0.73,0.87) | <0.000 01 | 0.77 | (0.71,0.85) | <0.000 01 |
早产儿SGA | 2.64 | (1.85,3.77) | <0.000 01 | 2.46 | (1.74,3.47) | <0.000 01 |
早产儿产房气管插管 | 2.50 | (1.39,4.50) | 0.002 | 2.50 | (1.39,4.51) | 0.002 |
早产儿5 min Apgar评分<7分 | 2.47 | (1.36,4.47) | 0.003 | 2.47 | (1.36,4.47) | 0.003 |
男性早产儿 | 1.49 | (1.43,1.55) | <0.000 01 | 1.49 | (1.43,1.55) | <0.000 01 |
早产儿机械通气 | 1.59 | (1.28,1.96) | <0.000 1 | 1.39 | (1.14,1.71) | <0.000 1 |
早产儿机械通气>7 d | 7.99 | (4.47,14.29) | <0.000 01 | 6.55 | (3.63,11.80) | <0.000 01 |
早产儿肺表面活性物质 | 3.46 | (1.96,6.11) | <0.000 1 | 3.46 | (1.96,6.11) | <0.000 1 |
早产儿使用类固醇 | 2.42 | (1.93,3.03) | <0.000 01 | 2.51 | (1.86,3.40) | <0.000 1 |
早产儿RDS | 3.40 | (2.01,5.75) | <0.000 01 | 3.23 | (1.93,5.41) | <0.000 01 |
早产儿PDA | 1.96 | (1.38,2.79) | 0.000 2 | 1.96 | (1.38,2.80) | 0.000 2 |
早产儿败血症 | 1.82 | (1.36,2.44) | <0.000 1 | 1.74 | (1.30,2.34) | <0.000 1 |
早产儿NEC | 1.62 | (1.18,2.22) | 0.003 | 1.62 | (1.18,2.22) | 0.003 |
早产儿ROP | 1.83 | (0.80,4.14) | 0.15 | 1.83 | (0.80,4.14) | 0.15 |
[1] |
World health organization:preterm birth[EB/OL]. (2018-02-19) [2021-12-01].
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
江苏省新生儿重症监护病房母乳质量改进临床研究协作组. 多中心回顾性分析极低及超低出生体重儿支气管肺发育不良的临床特点及高危因素[J]. 中华儿科杂志,2019,57(1):33-39. DOI:10.3760/cma.j.issn.0578-1310.2019.01.009.
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[35] |
|
[36] |
|
[37] |
原晋芳,韩彤妍. 绒毛膜羊膜炎与早产儿肺部疾病研究进展[J]. 中华实用儿科临床杂志,2019,34(10):794-796. DOI:10.3760/cma.j.issn.2095-428X.2019.10.018.
|
[38] |
|
[39] |
|
[40] |
|
[41] |
|
[42] |
|
[43] |
|
[44] |
|
[45] |
|
[46] |
|
[47] |
|
[48] |
|
[49] |
|
[50] |
|
[51] |
|
[1] | XU Baichuan, WANG Yan, ZHANG Peng, LI Yiting, LIU Feilai, XIE Yang. Research and Analysis of Screening Tools for Chronic Obstructive Pulmonary Disease Comorbidity Lung Cancer [J]. Chinese General Practice, 2025, 28(30): 3847-3852. |
[2] | XU Jialan, YAN Hong, WEN Jun, ZHOU Zitong, WANG Siyu. Prevalence of Potentially Inappropriate Medication in Older Adults with Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(30): 3815-3822. |
[3] | SHAO Xiaoying, SHAO Jie, ZHU Yan, SHAO Jinling, SHANG Ling, WU Zhenlian, ZHAO Yu, ZHANG Jiacai. Analysis of the Current Status of Iron Deficiency and Factors Affecting Iron Deficiency Anemia among Children Aged 6-36 Months in Guizhou Province [J]. Chinese General Practice, 2025, 28(27): 3368-3374. |
[4] | QUAN Jialin, ZHU Lin, SU Yu, CHEN Zekai, CHEN Ziqi, ZHANG Zhuofan. Research on the Improvement Effect of Exercise Modes on the Executive Function of Overweight or Obese Children or Adolescents: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(27): 3422-3431. |
[5] | ZHANG Tianyu, YU Haibo, CHEN Fei, LI Xin, ZHANG Jiajia, ZHAN Xiaokai, SHEN Man, TANG Ran, FAN Sibin, ZHAO Fengyi, HUANG Zhongxia. Meta-analysis of the Efficacy and Safety of Systemic Treatment for POEMS Syndrome [J]. Chinese General Practice, 2025, 28(27): 3447-3455. |
[6] | JIANG Shihua, ZHU Zheng, REN Yingying, ZHU Yaolei, WANG Yue, GAO Xibin. Meta Analysis of the Prevalence and Risk Factors of Myopia in Chinese Children and Adolescents [J]. Chinese General Practice, 2025, 28(24): 3043-3052. |
[7] | DING Xiang, LIU Jian, CHEN Xiaolu, ZHANG Xianheng. Chinese Herbal Medicine may be Associated with Lower Readmissions in Rheumatoid Arthritis Patients with Streptococcal Infection: a Matched Cohort Study [J]. Chinese General Practice, 2025, 28(24): 3005-3012. |
[8] | LI Hao, LI Jiangtao, LIU Dan, WANG Jianjun. Efficacy and Safety of Belimumab, Anifrolumab, and Telitacicept on the Treatment of Systemic Lupus Erythematosus: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(23): 2924-2933. |
[9] | WANG Xiaolin, LI Qiuyue, ZHOU Yanjun, ZHANG Jinhui, LIANG Tao. Incidence and Risk of Cardiovascular Toxicity with Fruquintinib in Metastatic Colorectal Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(23): 2934-2940. |
[10] | ZHOU Qian, WU Xiaomin, WANG Baohua, YAN Ruohan, YU Miao, WU Jing. Study on Nomogram Prediction Model for Risk of Gastric Cancer [J]. Chinese General Practice, 2025, 28(23): 2870-2877. |
[11] | YANG Ji, ZHANG Yao, ZHAO Yingqiang, ZHANG Qiuyue. Evaluation of the Effectiveness of TCM Three-level Prevention and Control Model in the Management of Patients with Coronary Heart Disease and Stroke: a Single-center, Prospective Cohort Study [J]. Chinese General Practice, 2025, 28(22): 2750-2761. |
[12] | MA Panpan, WANG Sijing, YOU Na, DING Dafa, LU Yibing. Efficacy and Safety of Danuglipron and Orforglipron in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis [J]. Chinese General Practice, 2025, 28(21): 2679-2685. |
[13] | ADILI Tuersun, CHENG Gang. Meta-analysis of the Efficacy and Safety of Finerenone in the Treatment of Type 2 Diabetic Nephropathy [J]. Chinese General Practice, 2025, 28(21): 2686-2691. |
[14] | HU Wanqin, YU Shenyan, CAO Xuehua, XIANG Feng, JIA Yu. Factors Associated with Precocious Puberty in Chinese Children: a Meta-analysis [J]. Chinese General Practice, 2025, 28(21): 2661-2671. |
[15] | TAN Yi, ZHU Lihong, YIN Zengwei, HOU Shunan, YU Houming. A Real-world Study of MRI-guided Intravenous Thrombolytic Therapy in Acute Ischemic Stroke [J]. Chinese General Practice, 2025, 28(20): 2508-2515. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||